Kairos Pharma Acquires Two Clinical Oncology Assets from Celyn Therapeutics.

Kairos Pharma has signed a term sheet to acquire two clinical-stage oncology assets, CL-273 and CL-741, from Celyn Therapeutics. The acquisition will add a pan-EGFR inhibitor and a Phase 1-ready c-MET inhibitor to Kairos Pharma's clinical pipeline, targeting the multi-billion dollar lung cancer market. The deal is part of Kairos Pharma's strategy to expand its clinical portfolio and address significant unmet medical needs in oncology.